Bronchogen
Also known as: Ala-Glu-Asp-Leu, AEDL
Buy in shop
Bronchogen from $185/kit
1 verified vendor, ≥99% purity, COAs included.
Key Facts: Bronchogen
- Category
- Bioregulators
- FDA Status
- Not FDA Approved
- Clinical Status
- Preclinical research, approved in Russia as supplement
- Administration
- Oral capsules or sublingual
- Typical Dose
- 10-20 mg daily
- Frequency
- Once or twice daily
- Duration
- 10-30 day cycles
Mechanism of Action
The proposed mechanism is the same one claimed for all Khavinson short peptides, and it is best treated as a working hypothesis rather than settled fact. Because the molecule is tiny, the idea is that it can slip into the cell nucleus, bind directly to specific stretches of DNA, and nudge which genes get switched on in bronchial cells. In cultured human bronchial epithelial cells the peptide was reported to shift expression of lung-identity and secretory genes such as NKX2-1, SCGB1A1 (the club-cell secretory gene), SCGB3A2, FOXA1 and FOXA2. It does not act on a classic surface receptor the way a hormone does. The DNA-binding claim comes from the researchers' own lab assays, and independent confirmation outside the Khavinson group is thin.
Research Summary
The strongest published study is Khavinson and colleagues in the journal Lung (2014), which tested the tetrapeptide in human embryonic bronchoepithelial cell cultures and reported changes in differentiation and proliferation markers including Ki-67, p53 and several lung-specific genes, with peptide binding said to occur in the major groove of DNA at guanine sites. That is in vitro cell-culture work, not a study in living animals or people. Beyond this and a handful of related Russian-language reports on lung inflammation and fibrosis models, the literature is sparse and comes almost entirely from one research group. There are no randomized controlled trials, no human safety or efficacy data, and no replication by independent Western labs. So the honest read is: an interesting cell-culture signal and a plausible-sounding mechanism, but nothing that proves it does anything useful in a real respiratory disease. Treat all marketing claims about COPD or asthma benefit as unproven.
Dosing Information
Note: Animal study doses may not translate directly to humans.
Typical Dosingⓘ
Community experience
10-20 mg daily
10-20 mg daily
Once or twice daily
Respiratory/bronchial bioregulator from Khavinson research. Often used for COPD, bronchitis, asthma support, and general lung health. Run in cycles of 10-30 days. Can be combined with other bioregulators.
Research Dosingⓘ
Scientific studies
Doses from bioregulator supplement protocols
Doses from Studies
10-20 mg daily
Duration
10-30 day cycles
Administration
Oral capsules or sublingual
Timing & Administration
Best Time to Take
Morning on empty stomach
Once or twice daily
Food Recommendation
Take on empty stomach
Why This Timing?
Peptide bioregulators typically taken fasted for optimal absorption
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally well-tolerated
- ●Limited safety data outside Russia
- ●Not FDA approved
References
- https://pubmed.ncbi.nlm.nih.gov/25015171/
- https://www.mdpi.com/1420-3049/26/22/7053
- https://link.springer.com/article/10.1007/s10522-009-9249-8
Research This Peptide Further
Buy in shop
Bronchogen from $185/kit
1 verified vendor, ≥99% purity, COAs included.
Frequently Asked Questions
What does Bronchogen do?
Bronchogen is a synthetic tetrapeptide bioregulator from the Khavinson family, usually written as Ala-Glu-Asp-Leu (the original lab paper used the order Ala-Asp-Glu-Leu, ADEL). It was designed to model peptides found in lung and bronchial tissue and is studied for respiratory cell repair and age-related lung decline. There are no approvals and no registered human clinical trials. Almost all of the real data is laboratory work in cell cultures.
How does Bronchogen work?
The proposed mechanism is the same one claimed for all Khavinson short peptides, and it is best treated as a working hypothesis rather than settled fact. Because the molecule is tiny, the idea is that it can slip into the cell nucleus, bind directly to specific stretches of DNA, and nudge which genes get switched on in bronchial cells. In cultured human bronchial epithelial cells the peptide was reported to shift expression of lung-identity and secretory genes such as NKX2-1, SCGB1A1 (the club-cell secretory gene), SCGB3A2, FOXA1 and FOXA2. It does not act on a classic surface receptor the way a hormone does. The DNA-binding claim comes from the researchers' own lab assays, and independent confirmation outside the Khavinson group is thin.
Is Bronchogen FDA approved?
No, Bronchogen is not currently FDA approved. Current status: Preclinical research, approved in Russia as supplement
What are the side effects of Bronchogen?
Reported side effects include: Generally well-tolerated, Limited safety data outside Russia, Not FDA approved. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of Bronchogen?
Community-reported common dose: 10-20 mg daily (Once or twice daily). Range: 10-20 mg daily. Administration: Oral capsules or sublingual. Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with Bronchogen or used in similar applications.
Livagen
PreclinicalLivagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala, or KEDA) from the family of short "peptide bioregulators" developed by Vladimir Khavinson's group in St. Petersburg, marketed in connection with liver and immune function. The proposed appeal is epigenetic: it has been reported to loosen tightly packed chromatin in aged cells, supposedly switching age-silenced genes back on. Evidence is limited to small laboratory and cell studies, mostly from one research group, with no clinical trials, so claims should be read with heavy skepticism.
BioregulatorsOvagen
PreclinicalOvagen is a synthetic ultra-short peptide, marketed as the tripeptide Glu-Asp-Leu (EDL), and grouped with the Khavinson-style "peptide bioregulators" promoted for liver and gastrointestinal support. Like its cousins in that family, it is claimed to act at the gene-expression level in a tissue-specific way. The honest picture: there is very little verifiable scientific data on Ovagen specifically, no clinical trials, and most of what is written about it comes from vendors rather than peer-reviewed research.
BioregulatorsCortagen
PreclinicalCortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro, AEDP) from Vladimir Khavinson's Russian peptide bioregulator program, designed as the defined-sequence stand-in for Cortexin, an older cattle brain cortex extract used in Russian neurology. It is studied mostly for nerve repair, brain function and aging, and it is not approved by the FDA or EMA. Real evidence is limited to animal experiments and Russian-institute work, with no Western randomized human trials.
BioregulatorsVesugen
PreclinicalVesugen is a synthetic tripeptide (Lys-Glu-Asp, or KED) from the Khavinson family of short peptide bioregulators, studied for vascular and neuroprotective effects. It is a research compound, not an approved drug, with no registered human clinical trials.
BioregulatorsChonluten
PreclinicalChonluten is a synthetic tripeptide (Glu-Asp-Gly, EDG) from the Khavinson bioregulator family, pitched as the lung and bronchial peptide, derived conceptually from the same program that produced Epitalon and Cortagen. It is researched for respiratory tissue and age-related lung decline, and it has no FDA or EMA approval. The evidence is essentially all preclinical or uncontrolled Russian clinical observation, with no randomized human trials.
BioregulatorsCrystagen
PreclinicalCrystagen is a synthetic tripeptide (Glu-Asp-Pro, or EDP) from the Khavinson family of short peptide bioregulators, studied as an immune and thymic regulator. It is a research compound, not an approved drug, with no registered human clinical trials. Note: many vendor pages list the wrong sequence; the correct one is Glu-Asp-Pro (EDP).
BioregulatorsWant updates on Bronchogen research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.